sefulness of Homoeopathic Medicine in the Treatment of Acid Peptic Disease
Phase 3
- Conditions
- Health Condition 1: K26- Duodenal ulcerHealth Condition 2: K20- EsophagitisHealth Condition 3: K30- Functional dyspepsiaHealth Condition 4: K25- Gastric ulcerHealth Condition 5: K29- Gastritis and duodenitisHealth Condition 6: K21- Gastro-esophageal reflux diseaseHealth Condition 7: K27- Peptic ulcer, site unspecified
- Registration Number
- CTRI/2022/03/040880
- Lead Sponsor
- DR ATHIRA VISWANATHAN M
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
ENDOSCOPICALLY CONFIRMED CASES OF ACID PEPTIC DISEASE
AGE BETWEEN 18 AND 65 YEARS OF BOTH SEXES.
Exclusion Criteria
Patients with congenital abnormalities in the Gastro intestinal tract
Patients with diagnosed cases of Acute Gastritis and Gastric cancer
Patients with immunodeficiency diseases like AIDS Cancer etc
Pregnant and lactating mothers
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method to find out the significant changes in Acid Peptic Disease after Homoeopathic intervention using upper GI EndoscopyTimepoint: 1 year
- Secondary Outcome Measures
Name Time Method To find out the significant changes in symptoms of Acid Peptic Disease after administration of Homoeopathic Medicine using Gastrointestinal Quality of Life index Scale <br/ ><br>To find out the recurrence and comorbidities in Acid Peptic DiseaseTimepoint: 1 Year follow up
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie homoeopathic medicine's efficacy in K26 duodenal ulcers and K25 gastric ulcers versus standard therapies?
How does homoeopathic treatment compare to proton pump inhibitors in managing K21 gastroesophageal reflux disease and K29 gastritis?
Which biomarkers predict response to homoeopathic therapy in patients with K27 peptic ulcer disease and K30 functional dyspepsia?
What adverse events are associated with homoeopathic medicine for K20 esophagitis and K26 duodenal ulcers in phase III trials?
Are there synergistic effects of homoeopathic medicine with natural compounds in treating K25 gastric ulcer and K29 gastritis?